Is Senti Biosciences, Inc. (SNTI) a Buy, Sell, or Hold?
NASDAQ : SNTI
Senti Biosciences, Inc.
$0.4038 USD
-$0.02 (-5.34%)
- Volume
- 190.19K
- Average Volume
- 254.06K
- Market Capitalization
- $12.57M
- P/E Ratio
- -0.21
- Dividend Yield
- 0.00%
- Price Target
- $6.00
- Year High
- $2.88
- Year Low
- $0.40
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $1.04
Company Overview
NASDAQ
Timothy K. Lu
Biotechnology
Healthcare
SNTI
39
US
USD
Liquidity Metrics
7.46
1.04
1.04
0.63
0.00
Sales & Valuation
$22000
330.90
4.88
-0.34
-1.20
Profitability
-$2.73
-$61.44M
-135650.00%
-135650.00%
-503.79%
-134.80%
P/E Metrics
-0.21
0.00
0.00
Analyst Price Target & Rating
$6.00
$6.00
$6.00
1/5
4 Analysts
-93.27%
Financial Health Scores
-17.52
3/9
$522K
$38.24M
$35.68M
-$51.55M
Key Metrics (TTM)
$22.78M
599.48
-0.48
1.04
-503.79%
-196.99%
-412.17%
-294.81%
7186 days
Company Executives
| Name | Title |
|---|---|
| Kanya Rajangam | President, Head of Research & Development and Chief Medical Officer |
| Thomas Chung | Vice President of Strategic Finance & Corporate Development |
| Wilson Wong | Scientific Co-Founder & Member of Scientific Advisory Board |
| Faraz Siddiqui | Senior Vice President of Technical Operations |
| Dee Olomajeye Dragon | Senior VP of People & Culture Strategy & Head of Administrative Operations |
| James J. Collins | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director |
| Timothy K. Lu | Co-Founder, Chief Executive Officer & Director |
| Jay Cross | Chief Financial Officer |
| Robert H. Cutler | Senior Vice President & Head of Legal Affairs |
Poll Results
No votes yet today — be the first to share your view!
About Senti Biosciences, Inc. (NASDAQ:SNTI) Stock
Senti Biosciences, Inc. is a pioneering company specializing in gene circuit technology. They focus on creating advanced cell and gene therapies that incorporate sophisticated gene circuits, essentially biological computers, to genetically reprogram cells. This allows the modified cells to interpret biological cues, make precise decisions, and react appropriately within their specific cellular surroundings. Their proprietary synthetic biology platform leverages readily available, "off-the-shelf" chimeric antigen receptor natural killer (CAR-NK) cells. This innovative approach is specifically designed to tackle formidable liquid and solid tumor cancers. Among their leading therapeutic candidates is SENTI-202. This "Logic Gated OR+NOT" off-the-shelf CAR-NK cell therapy is engineered to selec ... tively identify and destroy acute myeloid leukemia (AML) cells, critically leaving healthy bone marrow unharmed. Another key program, SENTI-301, is a multi-armed, ready-to-use CAR-NK cell therapy being developed for the treatment of hepatocellular carcinoma (HCC). Additionally, SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy, aims to precisely eliminate colorectal cancer (CRC) cells without damaging the body's healthy tissues. Established in 2016, Senti Biosciences maintains its headquarters in South San Francisco, California.
2026-07-15 07:30:00
SOUTH SAN FRANCISCO, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences Holdings, Inc. (NASDAQ: SNTI) (“SBH” or the “Company”) today announced a strategic transaction designed to sharpen its focus on next-generation controllable genetic medicines powered by its Regulator Dial™ technology platform (the “Retained Assets”) and unlock value for its Gene-Circuit-enabled pipeline, including SENTI-202, currently being advanced by its wholly owned subsidiary, Senti Biosciences, Inc.
2026-05-14 08:45:00
Secured strategic financing vehicle for up to $40 million Positive FDA feedback supports single-arm pivotal trial for potential registration of SENTI-202 in initial indication of Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Continued operational streamlining contributed to substantially reduced quarterly net loss and cash burn
2026-05-14 08:40:00
Following a Type B meeting with FDA, Senti Bio plans to proceed with a single-arm multi-center registrational trial for SENTI-202, building off the strong Phase 1 clinical results demonstrating deep and durable MRD-negative complete remissions
Frequently Asked Questions
-
What is the current Senti Biosciences, Inc. (SNTI) stock price?
-
Senti Biosciences, Inc.(NASDAQ:SNTI) stock price is $0.4038 in the last trading session. During the trading session, SNTI stock reached the peak price of $2.88 while $0.4029 was the lowest point it dropped to. The percentage change in SNTI stock occurred in the recent session was --5.34% while the dollar amount for the price change in SNTI stock was -$0.02.
-
SNTI's industry and sector of operation?
-
The NASDAQ listed SNTI is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of SNTI?
-
Kanya Rajangam | President, Head of Research & Development and Chief Medical Officer
Thomas Chung | Vice President of Strategic Finance & Corporate Development
Wilson Wong | Scientific Co-Founder & Member of Scientific Advisory Board
Faraz Siddiqui | Senior Vice President of Technical Operations
Dee Olomajeye Dragon | Senior VP of People & Culture Strategy & Head of Administrative Operations -
How many employees does SNTI have?
-
Number of SNTI employees currently stands at 39. SNTI operates from 2 Corporate Drive, South San Francisco, CA 94080, US.
-
Link for SNTI official website?
-
Official Website of SNTI is: https://www.sentibio.com
-
How do I contact SNTI?
-
SNTI could be contacted at phone #(650) 382-3281 and can also be accessed through its website. SNTI operates from 2 Corporate Drive, South San Francisco, CA 94080, US.
-
How many shares of SNTI are traded daily?
-
The average number of SNTI shares traded daily for last 3 months was 254.06K.
-
What is the market cap of SNTI currently?
-
The market value of SNTI currently stands at $12.57M with its latest stock price at $0.4038